The process of neuronal cell death following different types of injury involves apoptosis. Blocking the apoptotic cascade leading to cell death may prevent cell death and consequent loss follow- ing neuronal injury (neuroprotection). Loss of neural visual cells means effective loss of vision. Hence, neuroprotection strategies are needed to maintain neuronal integrity or to keep damaged cells functioning. In glaucoma, intraocular pressure (IOP) lower- ing aims to prevent the insult that leads to retinal ganglion cell (RGC) injury. Neuroprotection aims to maintain function despite injury. Over the past 20 years, many laboratory studies of poten- tial neuroprotective agents have yielded promising results. However, the same agents have subsequently failed to show significant neuroprotective activity in humans. Therefore, any evidence of neuroprotection in humans must be confirmed by controlled human clinical trials.

Falsini, B., Sieving, P., Bush, R., NeuroprotectionBenedetto Falsini, Ronald A. Bush, Paul A. Sieving, in Ryan, R. S. (ed.), Retina Vth Edition, Ryan S, Philadelphia 2013: 716- 733 [http://hdl.handle.net/10807/45752]

Neuroprotection Benedetto Falsini, Ronald A. Bush, Paul A. Sieving

Falsini, Benedetto;
2013

Abstract

The process of neuronal cell death following different types of injury involves apoptosis. Blocking the apoptotic cascade leading to cell death may prevent cell death and consequent loss follow- ing neuronal injury (neuroprotection). Loss of neural visual cells means effective loss of vision. Hence, neuroprotection strategies are needed to maintain neuronal integrity or to keep damaged cells functioning. In glaucoma, intraocular pressure (IOP) lower- ing aims to prevent the insult that leads to retinal ganglion cell (RGC) injury. Neuroprotection aims to maintain function despite injury. Over the past 20 years, many laboratory studies of poten- tial neuroprotective agents have yielded promising results. However, the same agents have subsequently failed to show significant neuroprotective activity in humans. Therefore, any evidence of neuroprotection in humans must be confirmed by controlled human clinical trials.
2013
Inglese
Retina Vth Edition
9781455707379
Falsini, B., Sieving, P., Bush, R., NeuroprotectionBenedetto Falsini, Ronald A. Bush, Paul A. Sieving, in Ryan, R. S. (ed.), Retina Vth Edition, Ryan S, Philadelphia 2013: 716- 733 [http://hdl.handle.net/10807/45752]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/45752
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact